



CELLSPRAY® TO BE USED IN THE NETHERLANDS AND DENMARK

Friday 13th February 2004, PERTH, AUSTRALIA: Clinical Cell Culture Ltd (C3, ASX: CCE) today announced that its CellSpray® and CellSpray® XP spray on skin products can be used in The Netherlands and Denmark.

CellSpray® and CellSpray® XP have been deemed suitable for a range of applications in The Netherlands including burns treatment and plastic surgery, and for a very specific use in Denmark through the National Hospital in Copenhagen.

C3 is currently in discussions with the National Hospital which has expressed an interest in testing CellSpray® in selected patients with Necrotising Fasciitis, a type of flesh-eating bacteria (<http://www.nnff.org/>).

C3 Chief Executive Officer Troels Jordansen said the Company was pleased with the acceptance of its products into these new markets and the association with the National Hospital in Copenhagen.

“Biological skin products have not typically been used in burns patients in The Netherlands or Denmark and our hope is that CellSpray®’s unique features, clinical results and positive health economical data will meet market needs in The Netherlands and convince surgeons in Copenhagen to adopt CellSpray®.”

Subject to the outcome of tests in Denmark and demand for the products in The Netherlands, C3 will supply these markets from its Perth based laboratory and has already appointed an agent to identify potential business.

GMP certification from the Belgium Health Authorities for the use of CellSpray® and CellSpray® XP in Germany and Austria is expected in March 2004.

About C3

Clinical Cell Culture is a publicly listed biomedical company which develops and distributes tissue-engineered cellular products for autologous skin replacement.

The Company’s lead products and product candidates are CellSpray®, cultured epithelial autograft spray suspension for the treatment of major burns and scars, ReCell®, autologous cell harvesting device for the treatment of small burns, pigment loss and scars and EpiGrow®, autologous epidermal derived fluid for the treatment of chronic wounds. C3’s products have been used on more than 1,600 patients to date.

C3 is currently internationalising its business setting up a production facility in Europe for CellSpray and in 2004, expects to be selling ReCell® in more than 15 countries around the world.

Media Release
Friday 13th February 2004
Page 2 of 2



www.clinicalcellculture.com

ENDS

For further information please contact:
Troels Jordansen or Gabriel Chiappini
Clinical Cell Culture
Ph: +61 (0)8 9355 6288
ccc@clinicalcellculture.com

OR

Claire Stannard
Porter Novelli
Ph: +61 (0)8 9386 1233
MB: 0409 189 410